• 공업화학전망
• /
• 제22권6호
• /
• pp.2-12
• /
• 2019

최근 암 면역치료는 임상연구에서 긍정적인 결과를 보이고 있으며 암 질환의 표준치료법으로 자리 잡아가고 있다. 암 면역치료는 암의 재발과 전이를 획기적으로 개선시킬 수 있다는 이점이 있다. 하지만 전체 암 환자의 15~20%에서만 치료 효과를 보이고 심각한 부작용을 유발할 수 있다는 임상적 한계가 있다. 이러한 문제점들을 개선하기 위해서 기존에 약물전달 또는 조직공학 분야에서 활용되었던 생체재료를 도입하여 면역치료의 효과를 개선하고 부작용은 줄이려는 시도가 활발하다. 본 기고문에서는 효율적인 암 면역치료를 위한 생체재료(나노입자, 리포좀, 미립구, 및 하이드로젤)에 관한 최신 연구동향을 다루고자 한다. 고기능성 생체재료 개발과 종양 면역학 분야의 깊은 이해는 효과적인 암 면역치료제를 개발하는데 있어서 매우 중요하다.

• Journal of Digestive Cancer Research
• /
• 제6권1호
• /
• pp.11-15
• /
• 2018

Chemotherapy and surgical resection are the mainstay of cancer treatment. Particularly for chemotherapy, although it is effective method to care, sometimes cure various cancers, there are many different status of cancer not being controlled by chemotherapy such as recurrence and resistance to chemotherapy. In order to overcome those difficulties during cancer therapy, immunotherapy targeting immune cells and immune associated factors to enhance cancer immunity has been highlighted. Innate immunity plays important roles on initial stage of cancer immunity that are detecting, killing cancer cells and initiating adaptive immunity for cancer. So many basic and clinical studies to manage innate immunity for cancer therapy have been going on, and most of them were to stimulate innate immune cells including dendritic cell, macrophage, monocyte, and natural killer cell in various ways. They showed promising results but still there are many things to be resolved before clinical application. Herein, I review the role of innate immune cells and therapeutic trials for colorectal cancer.

• 한국간담췌외과학회지
• /
• 제27권2호
• /
• pp.123-130
• /
• 2023

Intrahepatic cholangiocarcinoma is an aggressive, often fatal, malignancy that arises from the bile ducts. As it often presents with metastatic disease, surgery has limited utility. However, in some cases, neoadjuvant chemotherapy has provided the necessary reduction in tumor burden to allow for adequate resection. Consequently, new advances in neoadjuvant chemoradiation and targeted therapy are of interest with numerous case reports and small series published routinely; it is challenging to present a large case series or study given the overall rare frequency with which this malignancy is seen. Herein, we aim to summarize the newest advances in both neoadjuvant chemotherapy and targeted immunotherapy.

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.6.1-6.19
• /
• 2022

Chimeric antigen receptor (CAR) T cells, which express a synthetic receptor engineered to target specific antigens, have demonstrated remarkable potential to treat haematological malignancies. However, their transition beyond haematological malignancy has so far been unsatisfactory. Here, we discuss recent challenges and improvements for CAR T cell therapy against solid tumors: Antigen heterogeneity which provides an effective escape mechanism against conventional mono-antigen-specific CAR T cells; and the immunosuppressive tumor microenvironment which provides physical and molecular barriers that respectively prevent T cell infiltration and drive T cell dysfunction and hypoproliferation. Further, we discuss the application of CAR T cells in infectious disease and autoimmunity.

• Clinical and Experimental Reproductive Medicine
• /
• 제32권1호
• /
• pp.1-8
• /
• 2005

• Clinical and Experimental Pediatrics
• /
• 제46권5호
• /
• pp.418-422
• /
• 2003

• Journal of Digestive Cancer Research
• /
• 제10권2호
• /
• pp.117-119
• /
• 2022

• IMMUNE NETWORK
• /
• 제22권1호
• /
• pp.1.1-1.3
• /
• 2022

• 대한수의학회지
• /
• 제38권2호
• /
• pp.366-370
• /
• 1998

7일령의 송아지 4마리에 실험적으로 크립토스포리디움을 감염시키고 면역혈청, 면역초유 그리고 단크론항체(C6)을 투여하여 이들의 면역요법제로서의 효과를 측정하였다. 크립토스포리디움 감염후 4일째부터 3일간 하루 2회(200~500ml)씩 3종의 면역요법제를 송아지 1마리씩 각각 경구로 투여하였으며, 나머지 한마리의 대조송아지에는 인산 완충액을 경구로 투여하였다. 크립토스포리디움에 감염된 송아지들은 설사를 나타냈는데 대조송아지의 경우 감염후 3일째부터 9일간 설사증상을 나타냈다. 면역혈청, 면역초유 그리고 C6로 치료한 송아지들은 치료후 각각 3일, 2일, 5일째부터 정상에 가까운 분변을 배출하기 시작하였다. 면역혈청과 면역초유로 치료한 송아지들의 경우, 분변으로 배출되는 오시스트의 수가 대조송아지에 비해 현저하게 줄어들었다. 이러한 결과들은 실험에 제공된 면역요법제중 면역초유나 면역혈청이 크립토스포리디움에 감염된 송아지의 설사증상과 오시스트의 배출을 억제하는 효과가 있음을 나타내는 것이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권5호
• /
• pp.3109-3116
• /
• 2013

The majority of hepatocellular carcinoma (HCC) patients have a poor prognosis with current therapies, and new approaches are urgently needed. We have developed a novel therapeutic cancer vaccine platform based on tumor cell derived autophagosomes (DRibbles) for cancer immunotherapy. We here evaluated the effectiveness of DRibbles-pulsed dendritic cell (DC) immunization to induce anti-tumor immunity in BALB/c mouse HCC and humanized HCC mouse models generated by transplantation of human HCC cells (HepG2) into BALB/c-nu mice. DRibbles were enriched from H22 or BNL cells, BALB/c-derived HCC cell lines, by inducing autophagy and blocking protein degradation. DRibbles-pulsed DC immunization induced a specific T cell response against HCC and resulted in significant inhibition of tumor growth compared to mice treated with DCs alone. Antitumor efficacy of the DCs-DRibbles vaccine was also demonstrated in a humanized HCC mouse model. The results indicated that HCC/DRibbles-pulsed DCs immunotherapy might be useful for suppressing the growth of residual tumors after primary therapy of human HCC.